Effectiveness of mycophenolate mofetil in C3 glomerulonephritis

Data de publicació: 01/11/2015

Autors de IIS La Fe

Elena Román Ortiz

Autor
Santiago Mendizabal Oteiza

Autor

Autors aliens a IIS La Fe

Rabasco, C
Cavero, T
Rojas-Rivera, J
Olea, T
Espinosa, M
Cabello, V
Fernandez-Juarez, G
Gonzalez, F
Avila, A
Baltar, JM
Diaz, M
Alegre, R
Elias, S
Anton, M
Frutos, MA
Pobes, A
Blasco, M
Martin, F
Bernis, C
Macias, M
Barroso, S
de Lorenzo, A
Ariceta, G
Lopez-Mendoza, M
Rivas, B
Lopez-Revuelta, K
Campistol, JM
de Cordoba, SR
Praga, M
Spanish Grp Study Glomerular Dis

Abstract

C3 glomerulonephritis is a clinicopathologic entity defined by the presence of isolated or dominant deposits of C3 on immunofluorescence. To explore the effect of immunosuppression on C3 glomerulonephritis, we studied a series of 60 patients in whom a complete registry of treatments was available over a median follow-up of 47 months. Twenty patients had not received immunosuppressive treatments. In the remaining 40 patients, 22 had been treated with corticosteroids plus mycophenolate mofetil while 18 were treated with other immunosuppressive regimens (corticosteroids alone or corticosteroids plus cyclophosphamide). The number of patients developing end-stage renal disease was significantly lower among treated compared with untreated patients (3 vs. 7 patients, respectively). No patient in the corticosteroids plus mycophenolate mofetil group doubled serum creatinine nor developed end-stage renal disease, as compared with 7 (significant) and 3 (not significant), respectively, in patients treated with other immunosuppressive regimens. Renal survival (100, 80, and 72% at 5 years) and the number of patients achieving clinical remission (86, 50, and 25%) were significantly higher in patients treated with corticosteroids plus mycophenolate mofetil as compared with patients treated with other immunosuppressive regimens and untreated patients, respectively. Thus, immunosuppressive treatments, particularly corticosteroids plus mycophenolate mofetil, can be beneficial in C3 glomerulonephritis.

Dades de la publicació

ISSN/ISSNe:: 0085-2538, 1523-1755
Tipus:: Article
Pàgines:: 1153-1160
DOI:: 10.1038/ki.2015.227
PubMed:: 26221755
Factor d'Impacte:: 3,174 SCImago ℠
Quartil:: Q1 SCImago ℠

Documents

No hi ha documents

Mètriques

Filiacions

Keywords

complement; glomerulonephritis; membranoproliferative glomerulonephritis (MPGN)

Projectes associats

REGISTRO NACIONAL DE RECHAZO HUMORAL: ESTUDIO EPIDEMIOLOGICO MULTICENTRICO OBSERVACIONAL PROSPECTIVO PARA EVALUAR LAS CARACTERISTICAS CLINICAS, SEROLOGICAS E HISTOLOGICAS Y LA EVOLUCION A 5 AÑOS DEL RECHAZO HUMORAL POST-TRASPLANTE RENAL EN ESPAÑA

Investigador Principal: ISABEL BENEYTO CASTELLO

HUMORAL-KTX . 2011

UN ESTUDIO OBSERVACIONAL, NO INTERVENCIONISTA, MULTICÉNTRICO Y MULTINACIONAL DE PACIENTES CON SÍNDROME HEMOLÍTICO URÉMICO ATÍPICO (REGISTRO DE SHUA).

Investigador Principal: ELENA ROMÁN ORTIZ

ALE-ECU-2012-01 . 2013